Journal article
Approved but Unavailable: A Mystery-Caller Survey of Mifepristone Access in a Large Ontario City
Abstract
OBJECTIVES: Mifepristone/misoprostol (mife/miso) has been approved in Canada since 2017, and is available since 2018. Mife/miso does not require witnessed administration in Canada, and therefore most patients obtain a prescription for home use. We sought to determine the proportion of pharmacies in Hamilton, Ontario, Canada, a city of over 500 000, that had combination mife/miso in stock at any given time.
METHODS: A mystery-caller approach was …
Authors
Guarna G; Kotait M; Blair R; Vu N; Yakoub D; Davis R; Costescu D
Journal
Journal of Obstetrics and Gynaecology Canada, Vol. 45, No. 11,
Publisher
Elsevier
Publication Date
November 2023
DOI
10.1016/j.jogc.2023.06.009
ISSN
1701-2163